Literature DB >> 8244375

The Ah receptor nuclear translocator gene (ARNT) is located on q21 of human chromosome 1 and on mouse chromosome 3 near Cf-3.

B Johnson1, B A Brooks, C Heinzmann, A Diep, T Mohandas, R S Sparkes, H Reyes, E Hoffman, E Lange, R A Gatti.   

Abstract

We have mapped the Ah receptor nuclear translocator (ARNT) gene to a conserved linkage group located on mouse chromosome 3 and human chromosome 1. EcoRI-digested DNA from a panel of 17 human x mouse somatic cell hybrids was probed with a cDNA fragment of the human ARNT gene. Six of the 17 independent mouse x human hybrids were positive for human bands. Human chromosome 1 showed complete cosegregation with the gene, whereas discordant segregation was observed for all other human chromosomes. The human gene was localized to 1q21 by using DNA from mouse x human hybrid clones that retain translocations involving human chromosome 1, by segregation analysis in nine informative CEPH families, and by in situ hybridization. The mouse homologue was mapped to mouse chromosome 3 using a panel of 16 hamster x mouse somatic cell hybrids. Six of 16 mouse x hamster hybrids were positive for mouse bands, showing complete concordance with mouse chromosome 3. The mouse Arnt gene was regionally mapped on chromosome 3, using linkage analysis in an interspecific backcross. The results indicate that the mouse gene resides about 40 cM from the centromere and about 10 cM proximal to Cf-3, the gene for tissue factor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244375     DOI: 10.1006/geno.1993.1377

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  2 in total

1.  The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion.

Authors:  F Salomon-Nguyen; V Della-Valle; M Mauchauffe; M Busson-Le Coniat; J Ghysdael; R Berger; O A Bernard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Takaaki Hato; Jun Yamanouchi; Tatsushiro Tamura; Norimasa Hojo; Yasunari Niiya; Masashi Kohno; Shiro Bando; Yoshihiro Yakushijin; Kiyonori Takada; Ikuya Sakai; Masaki Yasukawa; Shigeru Fujita
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.